Sirtris Pharmaceuticals' SIRT1 Activator Controls Glucose as Well as a DPP-4 inhibitor in a Pre-Clinical Model of Type 2 DiabetesCAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 13, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, is presenting data today at the 2007 RBC Capital Markets Healthcare Conference on The Pharmaceutical Sweet Spot: Diabetes And Obesity Treatments Panel demonstrating that one of its new chemical entity (NCE) SIRT1 activators lowers plasma glucose and improves insulin sensitivity in a pre-clinical model of Type 2 Diabetes as well as or better than sitagliptin, a DPP-4 inhibitor. In addition, in an intraperitoneal glucose tolerance test, Sirtris' SIRT1 activator was shown to control glucose excursion as well as sitagliptin in this pre-clinical model of Type 2 Diabetes. In contrast to DPP-4 inhibitors, which lower glucose, SIRT1 activation appears to both lower glucose and also sensitize to insulin in these models.
The panel will be webcast live and can be accessed on the Sirtris website, www.sirtrispharma.com, in the investor relations section. A replay will be available approximately twenty-four hours after the presentation and will be archived on the company's website for two weeks.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, the potential therapeutic effects of SIRT1 activators for diseases of aging, such as Type 2 Diabetes and disorders, such as MELAS, the progress and results of pre-clinical studies of SIRT1 activators, and the potential of sirtuin modulators to receive regulatory approval. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company's product candidates will be safe or effective, or receive regulatory approval, the possibility that results of pre-clinical studies are not necessarily predictive of clinical trial results, the Company's potential inability to initiate and complete pre-clinical studies and clinical trials for its product candidates, the fact that none of the Company's product candidates has received regulatory approvals, the potential inability of the Company to gain market acceptance of the Company's product candidates, and those other risks factors that can be found in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
Sirtris Pharmaceuticals, Inc.
Michelle Dipp, M.D., Ph.D., 617-252-6920
For Sirtris Pharmaceuticals, Inc.
Sheryl Seapy, 949-608-0841
Posted: December 2007